C. Rubio et al., IDIOPATHIC PNEUMONIA SYNDROME AFTER HIGH-DOSE CHEMOTHERAPY FOR RELAPSED HODGKINS-DISEASE, British Journal of Cancer, 75(7), 1997, pp. 1044-1048
The risk of idiopathic pneumonia syndrome (IFS) in patients with Hodgk
in's disease (HD) undergoing high-dose chemotherapy (HDC) is significa
nt, and once developed IFS is potentially fatal. The aim of this study
was to quantify this risk accurately and determine prognostic factors
for its development and course. Using a computerized database, all pa
tients with HD treated with BCNU (carmustine) containing HDC and haema
topoietic support at The Royal Marsden between November 1985 and March
1994 were identified. Patient characteristics, previous treatments, d
isease status at HDC, dose of BCNU, incidence and severity of IFS and
survival were all determined and analysed. During the study period, 94
patients received HDC, of whom 26 (28%) had a first episode of IFS wi
thin a year of HDC and 23 within 6 months. The median time to presenta
tion after HDC was 93 days (range 12-336 days). The only factors that
significantly increased the risk of developing IFS on multivariate ana
lysis were dose of BCNU (P for trend = 0.03) and female sex (P = 0.04)
. Of these 26 patients, 14 had complete resolution of all symptoms, th
ree had persisting pulmonary symptoms at 6 months and the remaining ni
ne died of IFS at a median of 74 days (19-418 days). All the patients
who died from IFS had the first symptoms within 6 months of HDC and al
l received doses of BCNU > 475 mg m(-2) (Pier trend = 0.001). For wome
n receiving > 475 mg m(-2) the risk of death was significantly higher
than for men (P = 0.035) but not for those receiving < 475 mg m(-2). P
revious lung disease, persisting residual disease before HDC, previous
bleomycin or previous mantle radiotherapy did not increase either the
incidence of IFS or risk of a fatal outcome. We conclude that the mai
n avoidable risk factor for fatal IFS after HDC is dose of BCNU, and t
his is especially true for women. If < 475 mg m(-2) is given, even pat
ients with previous mantle radiotherapy and/or previous bleomycin have
a very low risk of developing fatal lung toxicity ii lung function te
sts are normal.